GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Navidea Biopharmaceuticals Inc (OTCPK:NAVB) » Definitions » Shiller PE Ratio

Navidea Biopharmaceuticals (Navidea Biopharmaceuticals) Shiller PE Ratio : (As of Apr. 27, 2024)


View and export this data going back to 1992. Start your Free Trial

What is Navidea Biopharmaceuticals Shiller PE Ratio?

Shiller PE for Stocks: The True Measure of Stock Valuation


Navidea Biopharmaceuticals Shiller PE Ratio Historical Data

The historical data trend for Navidea Biopharmaceuticals's Shiller PE Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Navidea Biopharmaceuticals Shiller PE Ratio Chart

Navidea Biopharmaceuticals Annual Data
Trend Dec13 Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22
Shiller PE Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

Navidea Biopharmaceuticals Quarterly Data
Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23
Shiller PE Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of Navidea Biopharmaceuticals's Shiller PE Ratio

For the Biotechnology subindustry, Navidea Biopharmaceuticals's Shiller PE Ratio, along with its competitors' market caps and Shiller PE Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Navidea Biopharmaceuticals's Shiller PE Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Navidea Biopharmaceuticals's Shiller PE Ratio distribution charts can be found below:

* The bar in red indicates where Navidea Biopharmaceuticals's Shiller PE Ratio falls into.



Navidea Biopharmaceuticals Shiller PE Ratio Calculation

For Shiller PE Ratio, the earnings of the past 10 years are inflation-adjusted and averaged. The result is used for P/E calculation. Since it looks at the average over the last 10 years, the Shiller PE Ratio is also called PE10.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The same calculation is applied here to individual companies.

Navidea Biopharmaceuticals's E10 for the quarter that ended in Sep. 2023 is calculated as:

For example, Navidea Biopharmaceuticals's adjusted earnings per share data for the three months ended in Sep. 2023 was:

Adj_EPS=Earnings per Share (Diluted)/CPI of Sep. 2023 (Change)*Current CPI (Sep. 2023)
=-0.02/129.8595*129.8595
=-0.020

Current CPI (Sep. 2023) = 129.8595.

Navidea Biopharmaceuticals Quarterly Data

Earnings per Share (Diluted) CPI Adj_EPS
201312 -2.000 98.326 -2.641
201403 -1.600 99.695 -2.084
201406 -1.400 100.560 -1.808
201409 -1.000 100.428 -1.293
201412 -1.000 99.070 -1.311
201503 -1.000 99.621 -1.304
201506 -1.200 100.684 -1.548
201509 -1.000 100.392 -1.294
201512 -0.400 99.792 -0.521
201603 -0.400 100.470 -0.517
201606 -0.800 101.688 -1.022
201609 0.000 101.861 0.000
201612 -0.400 101.863 -0.510
201703 10.400 102.862 13.130
201706 -0.600 103.349 -0.754
201709 -0.200 104.136 -0.249
201712 -0.600 104.011 -0.749
201803 -0.830 105.290 -1.024
201806 -0.290 106.317 -0.354
201809 -0.460 106.507 -0.561
201812 -0.400 105.998 -0.490
201903 -0.240 107.251 -0.291
201906 -0.240 108.070 -0.288
201909 -0.170 108.329 -0.204
201912 -0.150 108.420 -0.180
202003 -0.130 108.902 -0.155
202006 -0.110 108.767 -0.131
202009 -0.130 109.815 -0.154
202012 -0.110 109.897 -0.130
202103 -0.110 111.754 -0.128
202106 -0.090 114.631 -0.102
202109 -0.080 115.734 -0.090
202112 -0.120 117.630 -0.132
202203 -0.100 121.301 -0.107
202206 -0.100 125.017 -0.104
202209 -0.250 125.227 -0.259
202212 -0.110 125.222 -0.114
202303 -0.050 127.348 -0.051
202306 0.120 128.729 0.121
202309 -0.020 129.860 -0.020

Add all the adjusted EPS together and divide 10 will get our E10.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


Navidea Biopharmaceuticals  (OTCPK:NAVB) Shiller PE Ratio Explanation

Compared with the regular PE Ratio, which works poorly for cyclical businesses, the Shiller PE Ratio smoothed out the fluctuations of profit margins during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Shiller PE Ratio should give similar results to regular PE Ratio.

Compared with the PS Ratio, the Shiller PE Ratio makes the comparison between different industries more meaningful.


Be Aware

Shiller PE Ratio assumes that over the long term, businesses and profitability revert to their means. If a company's business model does not work in the future compared with the past, Shiller PE Ratio and PS Ratio will give false valuations.


Navidea Biopharmaceuticals Shiller PE Ratio Related Terms

Thank you for viewing the detailed overview of Navidea Biopharmaceuticals's Shiller PE Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Navidea Biopharmaceuticals (Navidea Biopharmaceuticals) Business Description

Traded in Other Exchanges
N/A
Address
4995 Bradenton Avenue, Suite 240, Dublin, OH, USA, 43017-3552
Navidea Biopharmaceuticals Inc is a biotechnology company specializied in precision medicine. Its products, precision immunodiagnostic agents and immunotherapeutic products are designed to assist in the identification of undetected diseases and to improve targeted treatment. The company's platform, known as Manocept technology, aims to develop next-generation targeted diagnostics and therapies for cancer, autoimmune conditions, and other inflammatory diseases. One of the company's products is Lymphoseek, a radioactive diagnostic agent indicated to locate lymph nodes.
Executives
Craig Dais officer: Chief Financial Officer 4995 BRADENTON AVENUE, SUITE 240, DUBLILN OH 43017
Dana J Moss director 4995 BRADENTON AVE, SUITE 240, DUBLIN OH 43017
Jill Stefanelli director 4995 BRADENTON AVE, SUITE 240, DUBLIN OH 43017
Josh M Wilson director 4795 BRADENTON AVE, STE 240, DUBLIN OH 43017
Scott John K Jr. director, 10 percent owner 30 BLUE HERON DR., GREENWOOD VILLAGE CO 80121
Agnieszka Winkler director C/O INTER-TEL, INCORPORATED, 1615 SOUTH 52ND STREET, TEMPE AZ 85281
Thomas F Farb director C/O SUMMIT PARTNERS, 222 BERKELEY ST 18TH FL, BOSTON MA 02116
Michel Mikhail officer: Chief Regulatory Officer 4995 BRADENTON AVE, SUITE 240, DUBLIN OH 43017
Malcolm G Witter director 4995 BRADENTON AVE, SUITE 240, DUBLIN OH 43017
Alexander L Cappello director C/O THE CHEESECAKE FACTORY INC, 26901 MALIBU HILLS ROAD, CALABASAS HILLS CA 91301
Amit Bhalla director 4995 BRADENTON AVE, SUITE 240, DUBLIN OH 43017
Joel H. Kaufman officer: Chief Business Officer 4995 BRADENTON AVE, SUITE 240, DUBLIN OH 43017
Jed Latkin officer: Interim COO 152 W. 57TH STREET, 4TH FLOOR, NEW YORK NY 10019
Sarah Kathryn Rouan director 4995 BRADENTON AVENUE, SUITE 240, DUBLIN OH 43017
Claudine Bruck director 4995 BRADENTON AVE, SUITE 240, DUBLIN OH 43017-3552